Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S (GILD) Stock Price & Analysis

3 Followers

GILD Stock Chart & Stats

CA$33.75-CA$0.36(-1.06%)

At close: Nov 12 4:00 PM EST

Day’s Range: CAD 33.75 - CAD 34.39
52-Week Range: CAD 23.97 - CAD 35.36
Previous Close: CAD 34.11
Volume: N/A
Average Volume (3M): 6,456
Market Cap: CAD 300.07B
Enterprise Value: CAD 63.44B
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): ―
Beta: 0.58
Next Earnings: Feb 04, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: Dec 15, 2026
Dividend Yield: 1.95%

Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S News

Gilead price target raised to $190 from $165 at Argus

Argus raised the firm’s price target on Gilead (GILD) to $190 from $165 and keeps a Buy rating on the shares. The stock has risen to new all-time highs following

18h agoGILD GIS

Gilead enters collaboration with TelevisaUnivision for Latin GRAMMY Awards

Gilead (GILD) Sciences announced a new collaboration with TelevisaUnivision and the 27th Latin GRAMMY Awards that will bring HIV prevention awareness into one of the most prominent cultural moments for

18h agoGILD GIS

Gilead’s Strong Results and Raised Outlook Drive Buy Rating and Price-Target Increase to $200

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Michael Okunewitch gave his Buy rating based on several factors, including Gilead’s

6d agoGILD GIS

Gilead announces results from PURPOSE 5 trial of lenacapavir

Gilead (GILD) Sciences announced results from the PURPOSE 5 trial showing significantly higher persistence-defined as consistent and continuous on-time use-among people starting twice-yearly injectable lenacapavir for HIV prevention as pre-exposure

6d agoGILD GIS

Gilead announces results from Phase 3 IDEAL study of livdelzi

Gilead (GILD) Sciences announced the detailed results from the Phase 3 IDEAL study, which demonstrated that the majority of participants living with PBC and treated with Livdelzi achieved the alkaline

1w agoGILD GIS

Gilead, Kite announce 23 presentations at ASH Annual Meeting

Gilead (GILD) Sciences and Kite, a Gilead Company announced 23 presentations, including 7 oral presentations, will be presented at the 68th American Society of Hematology, ASH, Annual Meeting and Exposition.

1w agoGILD GIS

Gilead to present clinical data, real-world evidence at HIV Glasgow

Gilead (GILD) Sciences announced its upcoming participation in the International Congress on Drug Therapy in HIV Infection, taking place from November 8-11. Results from more than 50 studies, including late-breaking

1w agoGILD GIS

Gilead price target raised to $200 from $177 at Scotiabank

Scotiabank analyst Louise Chen raised the firm’s price target on Gilead (GILD) to $200 from $177 and keeps an Outperform rating on the shares. The firm believes the price target

1w agoGILD GIS

Gilead price target raised to $183 from $163 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $183 from $163 and keeps an Overweight rating on the shares. Published first on TheFly –

1w agoGILD GIS

Gilead price target raised to $190 from $170 at JPMorgan

JPMorgan analyst Chris Schott raised the firm’s price target on Gilead (GILD) to $190 from $170 and keeps an Overweight rating on the shares. Published first on TheFly – the

1w agoGILD GIS

Gilead price target raised to $181 from $158 at Truist

Truist analyst Gregory Renza raised the firm’s price target on Gilead (GILD) to $181 from $158 and keeps a Buy rating on the shares. The company delivered a beat on

1w agoGILD GIS

Gilead Sciences: Hold Rating Maintained as PepStar Acquisition Boosts I&I Pipeline and Price Target Raised to $142

Goldman Sachs analyst Salveen Richter has maintained their neutral stance on GILD stock, giving a Hold rating on October 21. Salveen Richter has given his Hold rating due to a

2w agoGILD GIS

Gilead Buy Rating Reaffirmed as PepStar Deal Bolsters I&I Pipeline; Price Target Maintained at $163

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Gilead Sciences, with a price target of $163.00. Terence Flynn has given his Buy rating

2w agoGILD GIS

Gilead Buy Rating Reaffirmed as Strategic I&I Acquisition Supports Oral Combo Potential; $175 Price Target Maintained

Analyst Michael Yee from UBS maintained a Buy rating on Gilead Sciences and keeping the price target at $175.00. Michael Yee has given his Buy rating due to a combination

2w agoGILD GIS

GILD FAQ

What was Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S’s price range in the past 12 months?

Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S lowest stock price was C$23.97 and its highest was C$35.36 in the past 12 months.

What is Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S’s market cap?

Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S’s market cap is C$300.07B.

When is Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S’s earnings last quarter?

Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S released its earnings results on Oct 29, 2026. The company reported C$2.718 earnings per share for the quarter.

Is Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S pay dividends?

Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S pays a dividend of C$0.164 which represents an annual dividend yield of 1.95%. See more information on Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S dividends here

What is Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S’s EPS estimate?

Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S have?

Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S has 1,240,679,600 shares outstanding.

What happened to Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S’s price movement after its last earnings report?

Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S reported an EPS of C$2.718 in its last earnings report. Following the earnings report the stock price went up 3.339%.

Which hedge fund is a major shareholder of Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S?

Currently, no hedge funds are holding shares in TSE:GILD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S (GILD) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	15	6	1
Technical Analysis	3	6	1
Moving Averages	12	0	0

Technical Analysis >

Similar Stocks

Stocks similar to TSE:GILD
Company	Price & Change	Follow
TSE:NVSNovartis AG CAD Hedged CIBC CDR
TSE:SNYSanofi SA Unsponsored CDR Hedged Reg S
TSE:PFEPfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S
TSE:MRKMerck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S
TSE:AMGNAmgen Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S

Compare TSE:GILD Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

GILD Stock Chart & Stats

Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S News

Gilead price target raised to $190 from $165 at Argus

Gilead enters collaboration with TelevisaUnivision for Latin GRAMMY Awards

Gilead’s Strong Results and Raised Outlook Drive Buy Rating and Price-Target Increase to $200

Gilead announces results from PURPOSE 5 trial of lenacapavir

Gilead announces results from Phase 3 IDEAL study of livdelzi

Gilead, Kite announce 23 presentations at ASH Annual Meeting

Gilead to present clinical data, real-world evidence at HIV Glasgow

Gilead price target raised to $200 from $177 at Scotiabank

Gilead price target raised to $183 from $163 at Morgan Stanley

Gilead price target raised to $190 from $170 at JPMorgan

Gilead price target raised to $181 from $158 at Truist

Gilead Sciences: Hold Rating Maintained as PepStar Acquisition Boosts I&I Pipeline and Price Target Raised to $142

Gilead Buy Rating Reaffirmed as PepStar Deal Bolsters I&I Pipeline; Price Target Maintained at $163

Gilead Buy Rating Reaffirmed as Strategic I&I Acquisition Supports Oral Combo Potential; $175 Price Target Maintained

GILD FAQ

Company Description

Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S

Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S (GILD) Earnings & Revenues

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium